Escitalopram vs Citalopram: Clinical Comparison

Introduction to Efficacy and Safety

The American College of Physicians notes that escitalopram demonstrates statistically and clinically superior efficacy compared to citalopram, with a modest effect size (relative benefit 1.14, 95% CI 1.04-1.26) 1
Escitalopram separates from placebo by week 1, while citalopram requires 4-6 weeks to demonstrate statistical superiority over placebo 2

The American Academy of Child and Adolescent Psychiatry recommends escitalopram due to its lowest propensity for drug-drug interactions among all SSRIs, making it the safest choice for patients on multiple medications 3
Citalopram has moderate CYP450 interactions, particularly affecting drugs metabolized by CYP2D6 3
The American Family Physician notes that this advantage is particularly important in elderly patients and those with medical comorbidities requiring polypharmacy 4

The FDA issued a 2012 boxed warning limiting citalopram to maximum 40 mg/day (20 mg/day in adults >60 years) due to dose-dependent QT prolongation 5, 6
Citalopram is associated with QT prolongation leading to Torsade de Pointes, ventricular tachycardia, and sudden death at higher doses 3
Escitalopram has lower risk of QT prolongation and presents a safer cardiac profile 6
The American Academy of Child and Adolescent Psychiatry recommends avoiding citalopram entirely in patients with long QT syndrome, cardiac disease, or those taking QT-prolonging medications 3

The American Family Physician recommends escitalopram: 10-20 mg/day (start 10mg) and citalopram: 20-40 mg/day (start 20mg), with maximum 20mg/day in elderly 4
No dose adjustment needed for escitalopram in renal or hepatic disease, while citalopram requires consideration in hepatic impairment 4

The American Family Physician recommends escitalopram as the preferred agent for elderly patients due to its superior tolerability profile, lack of dose adjustment requirements, and absence of cardiac concerns at therapeutic doses 4

Choose escitalopram as first-line unless cost is prohibitive, patient has previously responded well to citalopram, or patient requires doses >20mg equivalent 4, 3
Mandatory citalopram avoidance in patients with cardiac disease or QT prolongation risk factors, age >60 years requiring doses >20mg, concomitant QT-prolonging medications, or multiple drug interactions via CYP2D6 3, 5, 6

Monitor for suicidality closely in first 1-2 months and after dose changes, with baseline ECG recommended for citalopram in at-risk patients but not routinely required for escitalopram 5, 3, 6

The American College of Cardiology is not mentioned in this article, however, Praxis Medical Insights recommends escitalopram as a preferred agent for elderly patients with depression due to its efficacy and tolerability profile 7
Escitalopram has a minimal effect on cytochrome P450 enzymes, resulting in a lower propensity for drug interactions 7
The Mayo Clinic suggests that citalopram is associated with a higher risk of QT interval prolongation at higher doses, a concern particularly relevant in elderly patients or those with heart disease 8
Escitalopram presents a lower risk of discontinuation syndrome compared to other SSRIs 7

The recommended dosage for escitalopram is 10-20 mg/day 7
The recommended dosage for citalopram is 20-40 mg/day, with caution not to exceed 20 mg/day in elderly patients due to the risk of QT interval prolongation 7

Regular assessment of therapeutic response and adverse effects is necessary, starting within 1-2 weeks of therapy initiation, as suggested by the Annals of Internal Medicine 9
Treatment modification is recommended if the patient does not have an adequate response within 6-8 weeks 9